BR0311983A - Métodos para detectar células neoplásticas ativadas por ras em uma amostra biológica, para diagnosticar um neoplasma ativado por ras em um animal, para tratar ou melhorar um neoplasma ativado por ras em um animal, para diagnosticar a presença de um neoplasma em um mamìfero, para detectar células neoplásticas tendo um fenótipo particular em uma amostra biológica, para diagnosticar um neoplasma tendo um fenótipo particular em um animal, e tratar ou melhorar um neoplasma tendo um fenótipo particular em um animal - Google Patents
Métodos para detectar células neoplásticas ativadas por ras em uma amostra biológica, para diagnosticar um neoplasma ativado por ras em um animal, para tratar ou melhorar um neoplasma ativado por ras em um animal, para diagnosticar a presença de um neoplasma em um mamìfero, para detectar células neoplásticas tendo um fenótipo particular em uma amostra biológica, para diagnosticar um neoplasma tendo um fenótipo particular em um animal, e tratar ou melhorar um neoplasma tendo um fenótipo particular em um animalInfo
- Publication number
- BR0311983A BR0311983A BR0311983-1A BR0311983A BR0311983A BR 0311983 A BR0311983 A BR 0311983A BR 0311983 A BR0311983 A BR 0311983A BR 0311983 A BR0311983 A BR 0311983A
- Authority
- BR
- Brazil
- Prior art keywords
- neoplasm
- ras
- animal
- activated
- particular phenotype
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"MéTODOS PARA DETECTAR CéLULAS NEOPLáSTICAS ATIVADAS POR RAS EM UMA AMOSTRA BIOLóGICA, PARA DIAGNOSTICAR UM NEOPLASMA ATIVADO POR RAS EM UM ANIMAL, PARA TRATAR OU MELHORAR UM NEOPLASMA ATIVADO POR RAS EM UM ANIMAL, PARA DIAGNOSTICAR A PRESENçA DE UM NEOPLASMA EM UM MAMìFERO, PARA DETECTAR CéLULAS NEOPLáSTICAS TENDO UM FENóTIPO PARTICULAR EM UMA AMOSTRA BIOLóGICA, PARA DIAGNOSTICAR UM NEOPLASMA TENDO UM FENóTIPO PARTICULAR EM UM ANIMAL, E PARA TRATAR OU MELHORAR UM NEOPLASMA TENDO UM FENóTIPO PARTICULAR EM UM ANIMAL". A presente invenção prove um método de diagnosticar neoplasmas tendo um fenótipo particular, empregando vírus oncolíticos que se replicam seletivamente nos neoplasmas tendo o fenótipo particular. Por exemplo, o reovírus não se replica em células normais. Entretanto, o reovírus replica-se seletivamente em células com um trajeto de ras ativado, que conduz à morte destas células. Portanto, uma célula que torna-se neoplástica, devido a, pelo menos em parte, atividades elevadas de trajeto do ras, podem ser diagnosticadas por sua susceptibilidade à replicação do reovírus. Esta invenção pode ainda ser aplicada, usando-se outros vírus oncolíticos, ao diagnóstico e/ou tratamento de outros tumores, tais como tumores sensíveis a interferon, tumores deficientes em p53 e tumores deficientes em Rb. São também aqui providos kits úteis no diagnóstico ou tratamento descrito aqui.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39203102P | 2002-06-28 | 2002-06-28 | |
US44318803P | 2003-01-29 | 2003-01-29 | |
PCT/CA2003/000951 WO2004003562A2 (en) | 2002-06-28 | 2003-06-25 | Oncolytic viruses as phenotyping agents for neoplasms |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0311983A true BR0311983A (pt) | 2005-04-26 |
Family
ID=30003222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0311983-1A BR0311983A (pt) | 2002-06-28 | 2003-06-25 | Métodos para detectar células neoplásticas ativadas por ras em uma amostra biológica, para diagnosticar um neoplasma ativado por ras em um animal, para tratar ou melhorar um neoplasma ativado por ras em um animal, para diagnosticar a presença de um neoplasma em um mamìfero, para detectar células neoplásticas tendo um fenótipo particular em uma amostra biológica, para diagnosticar um neoplasma tendo um fenótipo particular em um animal, e tratar ou melhorar um neoplasma tendo um fenótipo particular em um animal |
Country Status (20)
Country | Link |
---|---|
US (3) | US7306902B2 (pt) |
EP (2) | EP1890151B1 (pt) |
JP (1) | JP2005531306A (pt) |
CN (1) | CN1666105B (pt) |
AR (1) | AR039768A1 (pt) |
AT (2) | ATE377754T1 (pt) |
AU (2) | AU2003245760B2 (pt) |
BR (1) | BR0311983A (pt) |
CA (1) | CA2487824C (pt) |
DE (1) | DE60317331T2 (pt) |
DK (2) | DK1520175T3 (pt) |
ES (2) | ES2292981T3 (pt) |
HK (2) | HK1069877A1 (pt) |
IL (2) | IL165498A0 (pt) |
MX (1) | MXPA04012414A (pt) |
NZ (1) | NZ537116A (pt) |
PT (1) | PT1890151E (pt) |
SI (1) | SI1890151T1 (pt) |
TW (3) | TWI334444B (pt) |
WO (1) | WO2004003562A2 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
WO2004009763A2 (en) | 2002-07-24 | 2004-01-29 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2005007824A2 (en) * | 2003-07-08 | 2005-01-27 | Arizona Board Of Regents | Mutants of vaccinia virus as oncolytic agents |
WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
CA2617600A1 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Attenuated reovirus |
WO2007075879A2 (en) * | 2005-12-22 | 2007-07-05 | Memorial Sloan-Kettering Cancer Center | Method for detection of cancer cells using virus |
ES2551306T3 (es) * | 2006-02-13 | 2015-11-17 | Oncolytics Biotech Inc. | Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
KR101585702B1 (ko) * | 2008-05-22 | 2016-01-15 | 제일약품주식회사 | 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성 |
AU2009253682B2 (en) * | 2008-05-27 | 2015-09-17 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
WO2010080909A1 (en) * | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
EP2764119A2 (en) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
WO2015089280A1 (en) * | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ(mva)の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
CN116440176A (zh) | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
US10842835B2 (en) | 2016-05-25 | 2020-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CN117085047A (zh) * | 2016-09-27 | 2023-11-21 | 萨特治疗学有限公司 | 优化的溶瘤病毒及其用途 |
CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
WO2018148462A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
SI3596116T1 (sl) | 2017-03-16 | 2024-02-29 | Alpine Immune Sciences, Inc., | Imunomodulatorni proteini različice pd-l1 in njihove uporabe |
WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
EP3697810A2 (en) | 2017-10-18 | 2020-08-26 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
EP3801584B1 (en) | 2018-06-04 | 2023-09-27 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
KR20210091740A (ko) | 2018-11-06 | 2021-07-22 | 카리디 바이오테라퓨틱스, 인크. | 세포-매개된 종양용해 바이러스 요법용 향상된 시스템 |
JP2022511735A (ja) | 2018-11-21 | 2022-02-01 | インダプタ セラピューティクス インコーポレイテッド | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
AU2019389151A1 (en) | 2018-11-30 | 2021-06-10 | Alpine Immune Sciences, Inc. | CD86 variant immunomodulatory proteins and uses thereof |
BR112021016728A2 (pt) | 2019-02-27 | 2022-01-11 | Actym Therapeutics Inc | Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral |
CN116368221A (zh) | 2020-04-22 | 2023-06-30 | 因达普塔治疗公司 | 自然杀伤(nk)细胞组合物及其生成方法 |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5670330A (en) * | 1992-09-29 | 1997-09-23 | Mcgill University | Anti-tumor agent assay using PKR |
AU682854B2 (en) * | 1993-02-16 | 1997-10-23 | Onyx Pharmaceuticals | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
ES2315595T3 (es) | 1993-04-30 | 2009-04-01 | Wellstat Biologics Corporation | Composiciones para tratar cancer con uso de virus. |
EP0741580A4 (en) | 1993-12-14 | 2001-07-11 | Univ Johns Hopkins Med | CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY |
WO1995032300A1 (en) | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US6777177B1 (en) * | 1997-10-10 | 2004-08-17 | Vanderbilt University | Mammalian genes involved in viral infection and tumor suppression |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
CA2508238C (en) | 1997-08-13 | 2008-01-15 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
EP1032269B1 (en) | 1997-10-09 | 2007-08-29 | Wellstat Biologics Corporation | Treatment of neoplasms with interferon-sensitive, clonal viruses |
US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
EP1061806A4 (en) | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES |
CA2342203C (en) | 1998-08-31 | 2011-03-01 | Julian L. Ambrus | Method for removal of hiv and other viruses from blood |
AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
DE19934788B4 (de) * | 1999-07-27 | 2004-05-27 | T-Mobile Deutschland Gmbh | Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software |
MXPA02002772A (es) | 1999-09-17 | 2004-04-02 | Pro Virus Inc | Virus oncolitico. |
AU782020B2 (en) | 1999-11-12 | 2005-06-30 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
AR028040A1 (es) * | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas |
AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US20020037543A1 (en) * | 2000-06-26 | 2002-03-28 | Atkins Harold L. | Purging of cells using viruses |
WO2002004596A2 (en) | 2000-07-07 | 2002-01-17 | President And Fellows Of Harvard College | Diagnosing and treating cancer cells using mutant viruses |
WO2002039117A1 (en) | 2000-11-09 | 2002-05-16 | Oncolytics Biotech, Inc. | Methods for the treatment of cellular proliferative disorders |
US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
-
2003
- 2003-06-24 US US10/602,024 patent/US7306902B2/en not_active Expired - Lifetime
- 2003-06-25 AT AT03737795T patent/ATE377754T1/de not_active IP Right Cessation
- 2003-06-25 JP JP2004516379A patent/JP2005531306A/ja active Pending
- 2003-06-25 PT PT07021569T patent/PT1890151E/pt unknown
- 2003-06-25 DE DE60317331T patent/DE60317331T2/de not_active Expired - Lifetime
- 2003-06-25 CN CN03815353.XA patent/CN1666105B/zh not_active Expired - Lifetime
- 2003-06-25 AU AU2003245760A patent/AU2003245760B2/en not_active Expired
- 2003-06-25 EP EP07021569A patent/EP1890151B1/en not_active Expired - Lifetime
- 2003-06-25 SI SI200332164T patent/SI1890151T1/sl unknown
- 2003-06-25 ES ES03737795T patent/ES2292981T3/es not_active Expired - Lifetime
- 2003-06-25 AT AT07021569T patent/ATE555388T1/de active
- 2003-06-25 BR BR0311983-1A patent/BR0311983A/pt not_active IP Right Cessation
- 2003-06-25 DK DK03737795T patent/DK1520175T3/da active
- 2003-06-25 WO PCT/CA2003/000951 patent/WO2004003562A2/en active Application Filing
- 2003-06-25 DK DK07021569.4T patent/DK1890151T3/da active
- 2003-06-25 ES ES07021569T patent/ES2385845T3/es not_active Expired - Lifetime
- 2003-06-25 EP EP03737795A patent/EP1520175B1/en not_active Expired - Lifetime
- 2003-06-25 MX MXPA04012414A patent/MXPA04012414A/es active IP Right Grant
- 2003-06-25 NZ NZ537116A patent/NZ537116A/en unknown
- 2003-06-25 CA CA2487824A patent/CA2487824C/en not_active Expired - Lifetime
- 2003-06-26 TW TW098135545A patent/TWI334444B/zh not_active IP Right Cessation
- 2003-06-26 TW TW098118162A patent/TWI402345B/zh not_active IP Right Cessation
- 2003-06-26 AR ARP030102317A patent/AR039768A1/es unknown
- 2003-06-26 TW TW092117377A patent/TWI327167B/zh not_active IP Right Cessation
-
2004
- 2004-12-01 IL IL16549804A patent/IL165498A0/xx active IP Right Grant
-
2005
- 2005-04-18 HK HK05103306A patent/HK1069877A1/xx not_active IP Right Cessation
-
2007
- 2007-05-30 US US11/807,771 patent/US20080014577A1/en not_active Abandoned
-
2008
- 2008-06-26 HK HK08107121.9A patent/HK1112509A1/xx not_active IP Right Cessation
- 2008-08-28 AU AU2008207579A patent/AU2008207579B2/en not_active Expired
-
2010
- 2010-01-05 US US12/652,289 patent/US8222036B2/en not_active Expired - Lifetime
-
2012
- 2012-06-04 IL IL220139A patent/IL220139A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0311983A (pt) | Métodos para detectar células neoplásticas ativadas por ras em uma amostra biológica, para diagnosticar um neoplasma ativado por ras em um animal, para tratar ou melhorar um neoplasma ativado por ras em um animal, para diagnosticar a presença de um neoplasma em um mamìfero, para detectar células neoplásticas tendo um fenótipo particular em uma amostra biológica, para diagnosticar um neoplasma tendo um fenótipo particular em um animal, e tratar ou melhorar um neoplasma tendo um fenótipo particular em um animal | |
Peterson et al. | Evaluation of serum symmetric dimethylarginine concentration as a marker for masked chronic kidney disease in cats with hyperthyroidism | |
Fenton et al. | Natural history of schizophrenia subtypes: I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia | |
BRPI9912227A (pt) | método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método. | |
BR9916449A (pt) | Dispositivo de ensaio, métodos para determinação de uma condição de doença ou de um distúrbio ou de uma propensão para o desenvolvimento de uma condição de doença ou de um distúrbio e para tratamento de câncer ou de uma propensão para o desenvolvimento de câncer em um animal humano ou não-humano, uso de um arranjo de moléculas, e, método para identificação de uma proteìna mimética em uma amostra quìmica ou biológica | |
ATE241139T1 (de) | Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays | |
ATE376187T1 (de) | Nachweis von erkrankungen der nieren und behandlung | |
DE69022286D1 (de) | Reagenzien, Verfahren und Testsätze zum Nachweis von Amphetaminen durch einen Fluoreszenz-Polarisations-Immunoassay. | |
ATE217190T1 (de) | Test und reagentien zur identifizierung von antiproliferierenden stoffen | |
DE69841164D1 (de) | Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung | |
KR930703611A (ko) | 양막파열을 감지하는 진단방법과 이방법을 이용한 테스트키트 | |
BR7608467A (pt) | Processo e dispositivo para teste de gravidez,bem como processo para detecao de condicoes fisiologicas associadas a presenca de gonadotropinas na urina ou no soro | |
Patel et al. | Effect of undernutrition on the regional development of transmitter enzymes: glutamate decarboxylase and choline acetyltransferase | |
BRPI0519060A2 (pt) | kit de teste rÁpido para a detecÇço e a localizaÇço de élceras nos eqÜinos e seu mÉtodo de produÇço | |
Michael et al. | A longitudinal study of the persistence of increased creatinine and concordance between kidney biomarkers in cats and dogs | |
Thomas et al. | Total bilirubin assay differences may cause inconsistent treatment decisions in neonatal hyperbilirubinaemia | |
Franchini et al. | Tubulo-Interstitial Nephropathies by Industrial Chemicals | |
Kure et al. | Benzo (a) pyrene-albumin adducts in humans exposed to polycyclic aromatic hydrocarbons in an industrial area of Poland. | |
Börmer | Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen | |
Cramer et al. | Serum chemistry values for the beagle | |
Hamazaki et al. | Intraneural perineurioma involving the ulnar nerve | |
Guthrie | Screening of newborn infants | |
Sweeney et al. | Advances in early fetal loss research: importance for risk assessment. | |
ATE266870T1 (de) | Verfahren zur erfassung oder quantifizierung von basophilen und eosinophilen | |
Cain | XXII. Exploration of Metabolic Patterns in Mentally Deficient Children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 DA RPI 2116 DE 26/07/2011. |